AR015926A1 - Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades - Google Patents

Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades

Info

Publication number
AR015926A1
AR015926A1 ARP980103512A ARP980103512A AR015926A1 AR 015926 A1 AR015926 A1 AR 015926A1 AR P980103512 A ARP980103512 A AR P980103512A AR P980103512 A ARP980103512 A AR P980103512A AR 015926 A1 AR015926 A1 AR 015926A1
Authority
AR
Argentina
Prior art keywords
cells
diseases
cells obtained
oncogene
stages
Prior art date
Application number
ARP980103512A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19731154A external-priority patent/DE19731154C2/de
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR015926A1 publication Critical patent/AR015926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Células para su aplicacion en la terapia génica que son obtenibles por: a) aislamiento de células a partir de la sangre o de los líquidos corporales quecontienen células; b) cultivacion de las células obtenidas en la etapa a) en un medio de cultivoq ue contiene gangliosidos, fosfolípidos, glicolípidos y/ofactores de crecimiento; c) facultativamente, inmortalizacion de las células obtenidas en las etapas a) o b) por trasnformacion con un oncogén, activacion deun oncogén o inactivacion de ungen s upresor; d) transfeccion de las células obtenidas en las etapas a) y b) o en la etapa c) con una estructura artificial deácido nucleico para la terapia génica, que contiene un gen efector, el cual puede ser activado por apropiados sistemas depromoto res de modo específico paracélulas diana, de modo específico para ciclos celulares, de modo específico para virus y/o por hipoxia; y la utilizacion de estas células para la preparacionde un medicamento destinado al tratamiento de unaenfermedad que s e selecciona entre el grupo que consta de tumores, leucemias, enfermedades autoinmunes,alergias, artritis, inflamaciones, rechazos de organos, reacciones de trasplante frente a hospedante, enfermedades de coagulacion de la sangre,enfermedades dela c irculacion, anemia, infecciones, enfermedades hormonales y lesiones de sistema nervioso central.
ARP980103512A 1997-07-21 1998-07-17 Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades AR015926A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19731154A DE19731154C2 (de) 1997-07-21 1997-07-21 Genetisch veränderte Endothelzellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
DE19752299 1997-11-26

Publications (1)

Publication Number Publication Date
AR015926A1 true AR015926A1 (es) 2001-05-30

Family

ID=26038441

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103512A AR015926A1 (es) 1997-07-21 1998-07-17 Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades

Country Status (14)

Country Link
US (1) US20020098166A1 (es)
EP (1) EP0893493A3 (es)
JP (1) JPH1189587A (es)
KR (1) KR19990014018A (es)
AR (1) AR015926A1 (es)
AU (1) AU757960B2 (es)
BR (1) BR9802542A (es)
CA (1) CA2237698A1 (es)
CZ (1) CZ227198A3 (es)
HU (1) HUP9801634A3 (es)
ID (1) ID20600A (es)
PL (1) PL327624A1 (es)
RU (1) RU2205029C2 (es)
TR (1) TR199801395A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787464B1 (fr) * 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
KR100636578B1 (ko) 1999-04-02 2006-10-19 히사미쓰 세이야꾸 가부시키가이샤 치료용 유전자 발현 염기서열 및 유전자 치료용 약제
CA2383093A1 (en) * 1999-09-23 2001-03-29 An-Go-Gen Inc. Cell-based gene therapy for the pulmonary system
US20030049635A1 (en) * 2000-11-08 2003-03-13 City Of Hope Measurement of mutation load using the p53 gene in human cells from paraffin embedded tissues
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
EP1487274B1 (en) 2002-03-15 2010-10-13 Duke University Tissue engineering
CA2479840A1 (en) * 2002-04-02 2003-10-16 William Marsh Rice University Redifferentiated cells for repairing cartilage defects
AU2003241107B2 (en) * 2002-05-16 2009-09-03 Absorber Ab Method of isolating an endothelial cell and method of donor specific crossmatching
JP2007531498A (ja) * 2003-07-15 2007-11-08 セダーズ−シナイ メディカル センター 疾患の診断、処置および予防におけるプレイオトロフィンの使用
KR100676922B1 (ko) * 2005-06-29 2007-02-05 정하철 혈 표시용 반지
IL286053B2 (en) 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
EP2205249B1 (en) * 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CA2723114C (en) * 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CN102083970B (zh) * 2008-07-21 2014-10-22 泰加生物工艺学公司 分化无核细胞及其制备方法
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2010061781A1 (ja) * 2008-11-25 2010-06-03 大塚製薬株式会社 ヒト単球由来治療用幹細胞およびその誘導方法
IN2012DE01792A (es) 2012-06-11 2015-10-16 Council Scient Ind Res
SG10201700459XA (en) 2012-07-20 2017-02-27 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
RU2018112710A (ru) 2015-09-24 2019-10-24 Сэллект Байотерапьютикс Лтд. Способы размножения мезенхимальных стволовых клеток (MSC) для применения в трансплантации
IL281425B (en) 2016-12-02 2022-07-01 Taiga Biotechnologies Inc Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017569A1 (en) * 1991-04-04 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immortalization of endothelial cells
FR2681609B1 (fr) * 1991-09-24 1994-12-30 Centre Nat Rech Scient Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.

Also Published As

Publication number Publication date
US20020098166A1 (en) 2002-07-25
ID20600A (id) 1999-01-21
PL327624A1 (en) 1999-02-01
EP0893493A3 (de) 2002-12-04
CA2237698A1 (en) 1999-01-21
HUP9801634A2 (hu) 1999-06-28
BR9802542A (pt) 2000-01-11
EP0893493A2 (de) 1999-01-27
HUP9801634A3 (en) 2003-07-28
RU2205029C2 (ru) 2003-05-27
CZ227198A3 (cs) 1999-02-17
AU7746698A (en) 1999-02-04
HU9801634D0 (en) 1998-09-28
KR19990014018A (ko) 1999-02-25
AU757960B2 (en) 2003-03-13
JPH1189587A (ja) 1999-04-06
TR199801395A2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
AR015926A1 (es) Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades
Rong et al. Hypoxic pretreatment of small extracellular vesicles mediates cartilage repair in osteoarthritis by delivering miR-216a-5p
Suárez-Álvarez et al. Epigenetic modulation of the immune function: a potential target for tolerance
CN107893076A (zh) CRISPR‑Cas9靶向敲除人乳腺癌细胞RASSF2基因及其特异性的sgRNA
Pan et al. SCF promotes dental pulp progenitor migration, neovascularization, and collagen remodeling–potential applications as a homing factor in dental pulp regeneration
CN109294985A (zh) 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
ES2773155T3 (es) Método para tratar leucemia usando un efecto reprogramante
RU2017121191A (ru) Методика размножения гамма-дельта Т-клеток
BRPI0411856A (pt) composições e métodos para o aumento da atividade de telomerase
US11053476B2 (en) Generation of cancer stem cells and use thereof
JP2017537625A5 (es)
BR0211491A (pt) Geração de células dendrìticas totalmente madura e estáveis de produtos de leucafereses para aplicações clìnicas
BRPI0610968A2 (pt) composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical
BR112020003026A2 (pt) ácidos nucleicos estabilizados codificando ácido ribonucleico mensageiro (mrna)
GB2617799A (en) Gene silencing
JP2007511219A5 (es)
Kato et al. RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer
Correale et al. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes
Etzion et al. Myocardial regeneration: present and future trends
Alnasser Stem cell challenge in cancer progression, oncology and therapy
Dong et al. A nano-immunotraining strategy to enhance the tumor targeting of neutrophils via in vivo pathogen-mimicking stimulation
CN105087477A (zh) miR-21反义核苷酸修饰的骨髓间充质干细胞的用途
RU2728592C1 (ru) Способ стимуляции презентирующей активности дендритных клеток
TW200413014A (en) Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation
EP0353290A1 (en) Selective inhibition of gene expression by photoactivatable oligonucleotides